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Abstract
Purpose Between30and50%offebrileneutropenicepisodes
are accounted for by infection. C-reactive protein (CRP) is a
nonspecific parameter for infection and inflammation but
might be employed as a trigger for diagnosis. The aim of the
studywastoevaluatewhether
18F-fluorodeoxyglucose (FDG)
positron emission tomography (PET)/CT can be used to
detect inflammatory foci in neutropenic patients with
elevated CRP and whether it helps to direct treatment.
Methods Twenty-eight consecutive patients with neutrope-
nia as a result of intensive chemotherapy for haematological
malignancies or myeloablative therapy for haematopoietic
stem cell transplantation were prospectively included.
18F-FDG PET/CT was added to the regular diagnostic
workup once the CRP level rose above 50 mg/l.
Results Pathological FDG uptake was found in 26 of 28 cases
despiteperipheralneutrophilcountslessthan0.1×10
−9/l in 26
patients: in the digestive tract in 18 cases, around the tract of
the central venous catheter (CVC) in 9 and in the lungs in 7
cases. FDG uptake in the CVC tract was associated with
coagulase-negative staphylococcal bacteraemia (p<0.001)
and deep venous thrombosis (p=0.002). The number of
patients having Streptococcus mitis bacteraemia appeared to
be higher in patients with grade 3 oesophageal FDG uptake
(p=0.08). Pulmonary FDG uptake was associated with the
presence of invasive fungal disease (p=0.04).
Conclusion
18F-FDG PET/CT scanning during chemotherapy-
induced febrile neutropenia and increased CRP is able to detect
localized foci of infection and inflammation despite the
absence of circulating neutrophils. Besides its potential role
in detecting CVC-related infection during febrile neutropenia,
the high negative predictive value of
18F-FDG PET/CT is
important for avoiding unnecessary diagnostic tests and
therapy.
Keywords Febrile neutropenia.Neutropenia. 18F-FDG
PET/CT.Invasive fungal disease.Mucosal barrier injury.
Septic thrombophlebitis
Introduction
Fever frequently develops during the profound neutropenia
induced by intensive chemotherapy but is not always
related to infection. It has long been the standard of care
to start treatment with broad-spectrum antibiotics promptly
once fever is observed because infection can be life-
threatening. Between 30 and 50% of febrile episodes are
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but invasive fungal pulmonary disease also occurs, and this
is the most important infectious cause of death in stem cell
recipients with mortality rates varying between 50 and 90%
[1–3]. Inflammation of the mucosa of the digestive tract
induced by cytotoxic treatment of haematological malig-
nancies manifests itself as mucositis and also leads to
elevated C-reactive protein (CRP) levels and fever, often
preceding certain types of bacteraemia typically with
Streptococcus mitis [4, 5].
Coagulase-negative staphylococcal (CoNS) bacteraemia
is seen in 30% of recipients of haematopoietic stem cell
transplantation (HSCT), and the central venous catheter
(CVC) usually implanted to manage most patients is
assumed to be the source of this bacteraemia. Transient
bacteraemia secondary to mucosal barrier injury, however,
may also lead to infection of the CVC and to catheter-
related thrombi [6–8].
Early recognition of infection contributes to better patient
outcomes[2, 9]. Unnecessary treatment, on the other hand, is
associated with side effects, the development of resistant
microorganisms and increased costs [10–12]. Hence, it is
important to attempt to distinguish fever due to mucosal
barrier injury and fever caused by infection whenever
possible.
18F-Fluorodeoxyglucose (FDG) positron emission
tomography (PET) proved capable of detecting localized
infectious and noninfectious inflammatory foci in immuno-
competent patients often before any anatomical changes
could be detected by conventional radiological techniques
[13–16]. Since
18F-FDG PET/CT depends not only on
neutrophils, it was hypothesized that this technique can also
be used in severely neutropenic patients [17–19].
We therefore performed a prospective observational
study among patients given myeloablative chemotherapy
for haematological malignancies. The aim of the study
was to determine whether
18F-FDG PET/CT allows
detection of inflammatory foci in patients with severe
neutropenia. We also explored the possibility of using
18F-FDG PET/CT to direct treatment of infectious compli-
cations in patients with elevated CRP levels during
neutropenia.
18F-FDG PET/CT was also evaluated for
pathological FDG uptake in the digestive tract because of
expected mucosal barrier injury.
Materials and methods
This was a prospective, descriptive study in which the
relationship between clinically defined infection (CDI) and
microbiologically defined infection (MDI) with
18F-FDG
PET/CT findings was defined. The Regional Ethics
Committee granted approval (CMO nr 11231).
Patients
All consecutive patients admitted between November 2006
and June 2007 to the Department of Haematology for
remission induction or consolidation chemotherapy for
acute myeloid leukaemia (AML) or myelodysplastic syn-
drome (MDS), or for a HSCT following myeloablative
therapy, were eligible provided treatment was expected to
result in neutropenia of more than 7 days duration. CRP
levels (upper limit of normal 10 mg/l) were determined
twice weekly and an
18F-FDG PET/CT scan was made as
soon as the CRP concentration exceeded 50 mg/l. Patients
were withdrawn from the study when there was evidence
of haemodynamic instability, diabetes mellitus if insulin
had to be administered within 4 h before the
18F-FDG
PET/CTscan or when glucose levels exceeded 15 mmol/l at
the time of
18F-FDG PET/CT. The study ended when the
patient was discharged. All patients gave written informed
consent.
18F-FDG PET/CT
An integrated PET/CT scanner (Siemens Biograph, Knox-
ville, TN, USA) was used for data acquisition.
18F-FDG
PET/CT was performed according to the European Associ-
ation of Nuclear Medicine (EANM) guidelines [20]. Before
FDG injection, patients fasted and glucose or insulin-
containing intravenous infusions were discontinued for
6 h. One hour after intravenous injection of 3.5 MBq/kg
FDG (Covidien, Petten, The Netherlands), a low-dose CT
of the area between the proximal femora and the base of the
skull was made for anatomical correlation and attenuation
correction of the PET data. Subsequently, emission images
of the same area were acquired. FDG uptake in the
digestive tract was compared to liver uptake. The digestive
tract was divided into three anatomical regions: oesophagus,
small bowel and colon. Lack of FDG uptake was graded as 0,
FDG uptake less than that in the liver was designated grade 1,
equal to liver uptake as grade 2 and as grade 3 when uptake
was more than that in the liver [21].
Low dose CT versus high-resolution CT (HRCT)
of the thorax
18F-FDG PET/CT was combined with HRCT of the thorax
when HRCT of the thorax was indicated because of
suspected invasive pulmonary fungal disease [10, 22–24].
The trigger for ordering HRCT for high-risk patients
included the following: signs or symptoms of pulmonary
disease, abnormal chest X-ray, a plasma galactomannan
index of >0.5 or fever persisting for >4 days despite broad-
spectrum antibiotic treatment.
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Monitoring of patients was performed according to standard
clinical practice. CRP determination was the only addition-
al test to the regularly scheduled laboratory tests.
18F-FDG
PET/CT was included in the regular diagnostic workup
when CRP exceeded 50 mg/l. Additional investigations to
confirm
18F-FDG PET/CT findings were only performed
when clinically justified. Epidemiological data, the number,
type and results of all diagnostic tests and treatment data
were registered in an electronic case record form (File-
Maker Pro 9.0).
Confirmation of
18F-FDG PET/CT findings
18F-FDG PET/CT reading was performed by two nuclear
medicine physicians. The low-dose CT provided anatomi-
cal reference for
18F-FDG PET abnormalities and was not
used for diagnostic purposes. On the same day, this was
reported to the attending physician. To be included in
patient management,
18F-FDG PET/CT findings had to be
supported by clinical evidence, microbiological tests and
routine radiology. Invasive techniques such as biopsy,
bronchoscopy or endoscopy were only performed when
clinically indicated.
The
18F-FDG PET/CT assessments were independently
re-evaluated (F.V. and W.O.) without knowledge of the final
diagnosis or the outcome. At a later stage, a differential
diagnosis of febrile neutropenia was made independently
without knowledge of the
18F-FDG PET/CT assessment by
an infectious disease specialist (F.V.) and a specialist in
infectious diseases in haematology (P.D.).
Clinical features
Bacteraemia was defined by the recovery of a microorgan-
ism from a single percutaneous blood culture, except for
members of the skin commensal flora such as CoNS or
coryneforms in which case an identical isolate had to be
recovered from two simultaneous sets of percutaneous
blood cultures, or from each lumen of a three- or four-
lumen CVC. Bacteraemia was deemed persistent when
blood cultures drawn on at least 2 separate days yielded
growth of the same isolate.
Catheter exit site infection was defined by the develop-
ment of any of the following manifestations within 2 cm of
the exit site: erythema or tenderness or induration or
seropurulent discharge (CDI). When any potential pathogen
was isolated from a specimen of the exit site or >15 colony-
forming units (cfu) were isolated in pure culture from
segment A (the external catheter) or segment B (the
subcutaneous part of the catheter), the infection was
deemed an MDI. Tunnel infection was defined by the
development of any of the following along the subcutane-
ous tract: cellulitis, erythema or tenderness or induration
with or without an exit site infection. In the absence of a
specimen of the tunnel infection, the cause was assumed to
be the same as that of an exit site infection when one
existed. Septic thrombophlebitis at the site of a CVC was
defined as persistent bacteraemia, and deep venous throm-
bosis as diagnosed by ultrasound or venography, and no
other source of infection explaining the persistence of
bacteraemia [25]. No specific testing for mucosal bowel
injury was performed. Citrulline levels, however, have
shown to be a reproducible measure for intestinal villous
mass [26]. Measurement of citrulline levels had been
performed in the majority of the patients. Citrulline levels
below 10 μmol/l have been interpreted as severe mucosal
bowel injury in other studies and replace other indirect
functional tests to assess cytotoxic effects of chemotherapy
[27]. Invasive fungal disease (IFD) was classified as
possible, probable and proven according to European
Organization for Research and Treatment of Cancer/
Mycoses Study Group (EORTC/MSG) guidelines [10].
Outcome parameters
The primary outcome parameter was the ability of
18F-FDG
PET/CT to locate an inflammatory (infectious or noninfec-
tious) focus during neutropenia. Secondary outcome param-
eters were the ability of
18F-FDG PET/CT to be used to
direct treatment of infectious complications in patients with
elevated CRP levels during neutropenia and the ability of
18F-FDG PET/CT to depict mucosal barrier injury.
Statistical analysis
Descriptive statistics were done to compare
18F-FDG PET/
CT with current practice regarding identification of infec-
tious or inflammatory foci explaining fever or other
potential signs of infection. Per anatomical area patients
with or without pathological FDG uptake were assessed for
the presence of a clinically and microbiologically defined
illness. Differences between patients with or without
pathological FDG uptake were tested using Fisher’s exact
tests for categorical variables. Differences were considered
to be statistically significant when the p value was less than
0.05 (two-sided).
Results
A total of 37 eligible patients provided written consent.
CRP levels remained below 50 mg/l in six cases, one
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Eur J Nucl Med Mol Imaging (2012) 39:120–128 123patient who experienced clinical deterioration withdrew
consent before
18F-FDG PET/CT could be performed and
18F-FDG PET/CT could not be performed in a further two
cases due to technical problems. Hence, 28 cases were
evaluated (Table 1).
On average, CRP reached 50 mg/l on day 12 after
starting chemotherapy. In 26 of 28 (93%) patients this
was accompanied by fever.
18F-FDG PET/CT was
performed a mean of 14 days after starting chemotherapy
when all patients were still profoundly neutropenic: 26
had peripheral neutrophil counts less than 0.1×10
−9/l.
Pathological FDG uptake was found in 26 of 28 cases
(93%) (Table 1). Grade 3 uptake was found in the
digestive tract in 18 cases, uptake in the CVC tract was
seen in 9 cases and abnormal pulmonary uptake was found
in 7 cases. In one case, localized FDG uptake in the right
thyroid lobe was found during the neutropenic phase
(Fig. 1) although the patient had no localizing symptoms.
He deteriorated 1 week later due to persistent candidemia.
A second
18F-FDG PET/CT scan, made 3 weeks after the
first scan, indicated abscess formation in the right thyroid
lobe, which was confirmed by surgical drainage and
culture.
FDG uptake in the CVC tract and CoNS bacteraemia
Of the 28 patients included in the study, 26 had a CVC.
FDG uptake in the CVC tract was only seen in nine
patients, all of whom had persistent CoNS bacteraemia
(p< 0 . 0 0 1 ) .T h ep r e s e n c eo fF D Gu p t a k ei nt h eC V Ct r a c t
was not related to clinical signs of exit site or tunnel
infection. Ultrasounds were only performed in the pres-
ence of local complaints, such as swelling of the arm, to
exclude deep venous thrombosis. An ultrasound of the
subclavian vein was performed in 11 of 26 (42%) patients,
amongst whom all 9 patients with FDG uptake in the CVC
tract. In case of deep venous thrombosis alone without
concomitant persistent CoNS bacteraemia, FDG uptake in
the CVC tract was never seen (see Table 1). Confirmed
deep venous thrombosis in combination with persistent
CoNS bacteraemia (septic thrombophlebitis) was present
insevenpatients.IncreasedFDGuptakeinthesubclaviantract
was found in six of these seven cases with confirmed septic
thrombophlebitis. In three patients FDG uptake in the CVC
tract was present without confirmed septic thrombophlebitis.
Persistent CoNS bacteraemia was present in all three of them,
but an ultrasound deep venous thrombosis was ruled out in
two of them and was not performed in the last patient.
In the patients without FDG uptake in the CVC tract
septic thrombosis was ruled out either by an ultrasound
ruling out thrombosis in 1 patient or the absence of
persistent bacteraemia in 14 patients. In only one patient
could septic thrombophlebitis not be ruled out definitely
as despite the presence of persistent CoNS bacteraemia
no ultrasound was performed. However, no clinical signs
of thrombosis were present. The positive predictive
value of
18F-FDG PET/CT for the presence of septic
thrombophlebitis was 67% and the negative predictive
value 94%.
In four of these six cases with septic thrombophlebitis
delineated by
18F-FDG PET/CT the first ultrasound was
negative and thrombosis could only be confirmed by a
second ultrasound, whereas
18F-FDG PET/CT had been
positive at the time of the first ultrasound (Fig. 2).
FDG uptake in the intestinal wall and Streptococcus mitis
bacteraemia
FDG uptake grade 2 or more was found in the digestive
tract, irrespective of the localization, in 24 of 28 (86%)
cases. Citrulline levels were known in 20 of 28 patients
(see Table 1). In two of the four patients in whom no
pathological FDG uptake was found in the digestive tract
citrulline levels were measured and below 10 μmol/l. FDG
uptake grade 2 or more in the oesophagus and colon were
not concomitant (p= 1 . 0 ) .G r a d e3F D Gu p t a k ei nt h ew a l l
of the oesophagus was seen in 11 cases. Endoscopy was
not performed in these patients. Of these 11 patients, 7
Fig. 1 Patient10with a Candida
abscess in the right thyroid lobe,
already present on the first (left)
18F-FDG PET/CT scan and
increased on a second scan
(right)
124 Eur J Nucl Med Mol Imaging (2012) 39:120–128(64%) had retrosternal complaints consistent with oeso-
phagitis (Fig. 3). Only one of the patients with retrosternal
complaints did have Streptococcus mitis bacteraemia. On
the other hand there appeared to be an association between
Streptococcus mitis bacteraemia and grade 3 oesophageal
FDG uptake (p=0.08), as five of seven patients with
Streptococcus mitis bacteraemia did have grade 3 FDG
uptake in the oesophagus (Table 2). Grade 3 FDG uptake
in the wall of the colon was found in 13 cases, but there
was no correlation with Streptococcus mitis bacteraemia
(p=0.2). Four patients had severe abdominal complaints
consistent with typhlitis and grade 3 colonic FDG uptake
was found in each case (Fig. 4).
Pulmonary FDG uptake and IFD
Proven invasive pulmonary fungal disease was not found,
but five patients had possible and two patients had probable
IFD (Fig. 5). Pulmonary FDG uptake was present in both
cases of probable IFD and in 3 of the 5 cases with possible
IFD and in only 2 of 21 patients without IFD. Pulmonary
FDG uptake therefore is associated with the presence of
IFD (p=0.04). Probable IFD was never present in the
absence of pulmonary FDG uptake.
Discussion
This study shows that localized foci of infection or
inflammation can be visualized by
18F-FDG PET/CT
during severe neutropenia. It has been shown before that
Fig. 3 Grade 3 FDG uptake in the oesophagus in patient 8. He
developed Streptococcus mitis bacteraemia during the neutropenic
phase
Fig. 2 Patient 4 with a swollen arm showed FDG uptake in the left
subclavian tract. Thrombosis of the subclavian vein was rejected by
normal ultrasound and he was discharged from the hospital 4 days
later. Two days later, the patient was readmitted for progressive
swelling of his arm. Deep venous thrombosis was confirmed by a
repeat ultrasound and blood cultures after removal of the CVC
remained positive for CoNS. The diagnosis of septic thrombophlebitis
of the subclavian vein was further supported by CT
Table 2 Streptococcus mitis bacteraemia and FDG uptake in the
digestive tract
S. mitis bacteraemia
present (n=7)
S. mitis bacteraemia
absent (n=21)
FDG uptake oesophagus
grade 3
5* 6
FDG uptake oesophagus
<grade 3
21 5
FDG uptake
colon grade 3
58
FDG uptake colon
<grade 3
21 3
Streptococcus mitis bacteraemia is most often found in patients with
grade 3 oesophageal FDG uptake
*p=0.076
Fig. 4
18F-FDG PET/CT
images of patient 1 during
severe right side abdominal
pain, diarrhoea and signs of
local peritonitis on physical
examination, showing grade 3
FDG uptake in the entire
colonic wall
Eur J Nucl Med Mol Imaging (2012) 39:120–128 12518F-FDG PET/CT is capable of visualizing localized areas
of inflammation by using the accelerated metabolism of
different activated inflammatory cells, other then neutro-
phils, such as macrophages and monocytes [17–19, 28].
This suggests that not only activated neutrophils, but also
other inflammatory cells play a role in visualizing localized
infection or inflammation by
18F-FDG PET/CT. Some
retrospective studies have reported the possibility of visual-
izing infectious foci by
18F-FDG PET/CT in neutropenic
patients, but only a minority of these patients were deeply
neutropenic at the time
18F-FDG PET/CT was performed in
contrast to all of our study patients [25, 29, 30]. In the largest
study so far among patients with multiple myeloma (n=248),
18F-FDG PET/CT was performed for disease staging in most
patients (n=199) and for infection workup in the remaining
49 patients [29]. In total, 165 infectious foci were detected in
that study. Neutropenia (<1.0×10
−9/l) was present in only 27
of 248 (11%) patients, however. Most probably FDG uptake
in other activated inflammatory cells is the explanation for
the visualization of inflammatory foci on
18F-FDG PET/CT
in the vast majority of patients in our study despite
neutrophil counts below 0.1×10
9/l [17, 18].
We found a clear correlation between FDG uptake in the
CVC tract and septic thrombophlebitis of the subclavian
vein. This supports the results of another study on the value
of
18F-FDG PET/CT in the diagnosis of septic thrombo-
phlebitis in which
18F-FDG PET/CT was prospectively
conducted in patients with suspected septic thrombophlebi-
tis [25, 30].
18F-FDG PET/CT showed pathological tracer
uptake in all nine patients with proven septic thrombophle-
bitis. Control patients in that study were collected from a
retrospective cohort of patients with deep venous thrombo-
sis without signs of infection in whom an
18F-FDG PET/CT
was performed for other reasons. Selection bias in that
study makes it impossible to calculate positive and negative
predictive values of
18F-FDG PET/CT regarding detection
of septic thrombophlebitis. Acaveatinourstudyis,however,
thatultrasoundwasonlyperformedonclinicalgrounds,sowe
m i g h th a v em i s s e da s y m p t o m a t i cd e e pv e n o u st h r o m b o s i s .
The negative predictive value of
18F-FDG PET/CT for the
presence of septic thrombophlebitis, however, can be
estimated to be high (94%) as in only one patient with
persistent bacteraemia was a deep venous thrombosis ruled
out solely on the absence of clinical signs. The positive
predictive value (67%) regarding septic thrombophlebitis on
the other hand might be underestimated in our study, because
ultrasound was not performed in all patients precluding these
patients from fulfilling the definition of septic thrombophle-
bitis. In three patients with FDG uptake in the subclavian
tract and persistent bacteraemia only one ultrasound was
performed. This is important as strikingly
18F-FDG PET/CT
seemed to precede detection of the abnormalities on
ultrasound of the subclavian vein in four cases of septic
thrombophlebitis. Therefore, pathological FDG uptake in the
CVC tract in patients with febrile neutropenia should not be
ignored as it might have important consequences in CVC
management, e.g. line removal, particularly when persistent
bacteraemia is diagnosed.
Pulmonary FDG uptake was frequently seen in this study
and was related with possible or probable IFD. In the
absence of pulmonary FDG uptake probable or definite IFD
was never the cause of fever at the time
18F-FDG PET/CT
was performed. An adequate comparison with HRCT,
which already has an added value in the early recognition
of life-threatening IFD, was not possible in our study
because
18F-FDG PET/CT and HRCT were not performed
within a time frame of several days in enough patients [22–
24]. Data show, however, that IFD can be visualized despite
profound neutropenia.
Metastatic infection was diagnosed in only one patient
with a Candida abscess in the thyroid gland. No other
metastatic foci were diagnosed by clinical symptoms or
Fig. 5
18F-FDG PET/CT images during the neutropenic phase after
allogeneic stem cell transplantation of patient 9 treated for multiple
myeloma. The
18F-FDG PET/CT scan shows extensive pulmonary
FDG uptake in both lungs (image shows pathological uptake in the
right lung). A chest X-ray made because of fever during the
neutropenic phase was unremarkable 3 days earlier. The HRCT scan
performed on the same day as the
18F-FDG PET/CT showed bilateral
consolidations, with a surrounding halo of ground glass supporting
probable IFD
126 Eur J Nucl Med Mol Imaging (2012) 39:120–128signs or other imaging techniques in our study. Conse-
quently, the negative predictive value of
18F-FDG PET/CT
for excluding clinically relevant metastatic foci of infection
is likely to be high assuming that these foci reveal
themselves due to intensive monitoring for symptoms and
signs when left untreated.
Substantial FDG uptake in the digestive tract was seen
in almost every case, but digestive tract uptake is
contentious as it is known to yield false-positive results
[31]. A visual grading for gastrointestinal activity was
chosen due to the variability in distribution and extent of
the enhanced FDG uptake in the gut. Theoretically,
chemotherapy may have influenced FDG uptake in the
liver, which was chosen as the organ of reference.
However, all patients were scanned at approximately the
same point in time during the course of treatment, thus
reducing the possibility of chemotherapy-induced variabil-
ity in liver uptake. Furthermore, none of the patients was
receiving metformin at the time the
18F-FDG PET/CT was
performed, excluding another important cause of increased
FDG uptake [32]
We specified uptake according to the anatomical region
and graded uptake comparing it to liver uptake to circumvent
this problem as has been done by others for staging disease
activity in colitis, which then showed a firm correlation with
disease activity [21, 33]. An interesting finding was the
possible correlation between oesophageal FDG uptake and
Streptococcus mitis bacteraemia, which was not seen in
colonic FDG uptake. These findings support the theory that
Streptococcus mitis bacteraemia originates from oesophageal
mucosal barrier injury [34]. Increased FDG uptake may be
the result of mucositis with or without infection since this
has been shown to be associated with thickening of the
oesophagus [35]. Besides mucosal barrier injury, there may
be an additional local factor such as infection due to
Streptococcus mitis of the mucosa, resulting in increased
FDG uptake [36]. Surprisingly no FDG uptake was found in
the digestive tract in some patients despite citrulline levels
below 10 μmol/l. Probably this supports the presence of an
additional inflammatory factor. Further studies on this
subject, however, should be performed.
Conclusion
18F-FDG PET/CT during chemotherapy-induced febrile
neutropenia and increased CRP is able to visualize
localized foci of infection and inflammation despite the
absence of neutrophils in the peripheral blood. Besides the
potential role of
18F-FDG PET/CT in early detection and
managing specific infectious complications during febrile
neutropenia, i.e. septic thrombophlebitis and metastatic
infection, its high negative predictive value may help in
avoiding unnecessary diagnostics and therapy.
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